Express delivery and influenza vaccination at the same time, Pfizer 20-valent pneumococcal conjugate vaccine Phase 3 clinical results are positive

▎ WuXi AppTec content team editor September 29, 2021, Pfizer announced that a phase 3 clinical trial of the 20-valent pneumococcal conjugate vaccine Prevnar 20 has achieved positive top-line results
.

The study evaluated the safety and immunogenicity of Prevnar 20 when vaccinated with seasonal influenza vaccine in adults over 65 years of age
.

The test results show that the immune response to all 20 serotypes when Prevnar 20 is vaccinated with seasonal influenza vaccine at the same time meets the non-inferiority standard when compared with the immune response evoked by the two vaccines with a single vaccination interval of 1 month
.

In addition, when vaccinated at the same time, the safety characteristics of Prevnar 20 are also similar to when each vaccine is vaccinated separately
.

A total of 1796 subjects were enrolled in this trial, and 1727 subjects completed the trial
.

Pfizer will announce detailed results of clinical trials in the future
.

Prevnar 20 is Pfizer's next-generation pneumococcal conjugate vaccine, containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14) included in Prevnar 13 (13-valent pneumococcal conjugate vaccine) , 18C, 19A, 19F, and 23F) capsular polysaccharide conjugates, and also contain the capsular polysaccharide conjugates of the other 7 serotypes (8, 10A, 11A, 12F, 15B, 22F, and 33F) that cause invasive pneumococcal disease They are associated with high mortality, antibiotic resistance, and/or meningitis
.

On June 8, 2021, the US FDA approved Prevnar 20 for the prevention of aggressive disease and pneumonia in adults 18 years of age or older
.

"We are encouraged by these results.
The trial data shows that the two vaccines can be vaccinated at the same time without affecting the immune protection provided by the vaccine or changing the safety characteristics
.

" Kathrin U, senior vice president and head of vaccine development at Pfizer Dr.
Jansen said, “This study provides further evidence to support simultaneous vaccination of pneumococcal conjugate vaccine and influenza vaccine.
This time it is used together with adjuvant-containing influenza vaccine
.

We will continue to work on vaccine development to help solve many problems.
The needs of respiratory diseases
.

" Dr.
Luis Jodar, Senior Vice President and Chief Medical Officer of Pfizer Vaccines, added: "Prevnar 20 and influenza vaccines are important to help adults prevent pneumococcal pneumonia and influenza, respectively
.

However, when people need it multiple times When you make an appointment to get these vaccines, the vaccination rate will drop
.

And allowing two vaccines at the same time can help more adults protect themselves from these two respiratory diseases
.

"Reference: [1] Positive Top- Line Results Of Pfizer'S Phase 3 Study Exploring Coadministration Of Prevnar 20™ With Seasonal Flu Vaccine In Older Adults Released.
Retrieved September 29, 2021, from https:// /positive-top-line-results-pfizers-phase-3-study-exploring Disclaimer: WuXi AppTec's content team focuses on introducing global biomedical health research progress
.

This article is for the purpose of information exchange only.
The opinions expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article
.

This article is not a treatment recommendation either
.

If you need guidance on the treatment plan, please go to a regular hospital for treatment
.